SPI.L

Spire Healthcare Group Plc
Spire Healthcare Grp - Share Buyback Programme
31st October 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3107K
Spire Healthcare Group PLC
31 October 2024
 

 

31 October 2024


 

Spire Healthcare Group plc

 

Share Buyback Programme

 

 

Spire Healthcare Group plc (LSE: SPI) ("Spire Healthcare" or "Company"), a leading independent healthcare group in the United Kingdom, announces a return of up to £5m cash to its shareholders through the means of an on-market share buyback programme (the "Programme").

Spire Healthcare has entered into a non-discretionary arrangement with Numis Securities Limited, trading as Deutsche Numis, to conduct the Programme on its behalf commencing today, 31 October 2024, and ending no later than 31 December 2024. Under these arrangements, Deutsche Numis will conduct the repurchases of the Company's ordinary shares of 1 pence each (the "Ordinary Shares") up to a maximum aggregate consideration of £5m and will make trading decisions in relation to the buyback of the Ordinary Shares within the programme terms and pre-set parameters.

 

The sole purpose of the Programme is to reduce the issued share capital of the Company, delivering further value for shareholders, and any Ordinary Shares purchased under the Programme will be cancelled.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 9 May 2024, pursuant to which the Company has authority to purchase a maximum of 40,413,223 Ordinary Shares (subject to certain limitations) (the "General Authority"). The aggregate number of Ordinary Shares which may be acquired by the Company pursuant to the Programme will not exceed the maximum number of Ordinary Shares which the Company is authorised to purchase pursuant to the General Authority.

 

Any purchase of Ordinary Shares made in relation to the Programme will be carried out on the London Stock Exchange. The buyback by Spire Healthcare will be executed in accordance with Chapter 9 of the UK Listing Rules and the terms of the General Authority. The Programme will be conducted within the parameters prescribed by the Market Abuse Regulation (EU) 596/2014, the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and with regard to regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures.

 

Spire Healthcare will announce any purchase by it of Ordinary Shares no later than 7.30 a.m. on the business day following the calendar day on which the purchase occurs.

 

The Company will make further announcements in due course following the completion of any repurchases. There is no guarantee that the Programme will be implemented in full or that any Ordinary Shares will be repurchased by the Company.

 

The Company confirms that it currently has no unpublished price sensitive information.

​

 

- Ends -

 

For further information please contact:

 

Spire Healthcare

Harbant Samra, CFO                                                     +44 (0)7881 672 365

 

Instinctif Partners

Julian Walker                                                                 +44 (0)7825 189 696

 

Registered Office and Head Office:

 

Spire Healthcare Group plc

3 Dorset Rise

London

EC4Y 8EN

Registered number 09084066

 

About Spire Healthcare

 

Spire Healthcare is a leading independent healthcare group in the United Kingdom, running 38 hospitals and over 50 clinics, medical centres and consulting rooms across England, Wales and Scotland. It operates a network of private GPs and provides occupational health services to over 800 corporate clients.

 

Working in partnership with over 8,600 experienced consultants, Spire Healthcare delivered tailored, personalised care to over 1 million inpatients, outpatients and daycase patients, and occupational health programme clients, in 2023, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom. It also delivers a range of private and NHS mental health, musculoskeletal and dermatological services under the Vita Health Group brand.

 

Spire Healthcare's well-located and scalable hospitals have delivered successful and award-winning outcomes, positioning the group well with patients, consultants, the NHS, GPs and Private Medical Insurance ('PMI') providers. 98% of Spire Healthcare's inspected locations are rated 'Good', 'Outstanding' or the equivalent by health inspectors in England, Wales and Scotland.

 

Spire Healthcare is listed on the London Stock Exchange and is a member of the FTSE 250.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFDWFASELSELS]]>
TwitterFacebookLinkedIn